RecruitingPhase 2NCT06976658

Glucokinase Activator in Monogenic Diabetes

Evaluating a Novel, Allosteric Glucokinase Activator in Monogenic Diabetes Secondary to Inactivating Glucokinase Mutations: a Randomised, Cross-over Trial


Sponsor

Chinese University of Hong Kong

Enrollment

44 participants

Start Date

Apr 30, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Evaluating a novel, allosteric glucokinase activator in monogenic diabetes secondary to inactivating glucokinase mutations: a randomised, cross-over trial


Eligibility

Min Age: 18 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dorzagliatin and a drug called matched placebo for people with diabetes mellitus and monogenic diabetes. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 74 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDorzagliatin

Dorzagliatin 50mg bd

DRUGmatched placebo

matched placebo


Locations(1)

3M, Diabetes and Endocrine Research Center

Hong Kong, Hong Kong

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06976658


Related Trials